1.34 USD
▲-0.01+4.69%
2026-08-03
市值
$859.64M
市盈率
—
EPS
-0.10
股息率
—
52 周区间
1.04 – 2.01
成交量
13.46M
Beta
0.60
目标价
4.25
52W 低 1.0452W 高 2.01
价格走势
公司简介
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...